XNAS · Healthcare · Biotechnology
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.38 | -0.43 | -13.16% | $40.9M | ❌ Miss | +0.00% | +0.04% | — |
| 2025-03-12 | Q3 2025 | -0.88 | -0.92 | -4.55% | $0 | ❌ Miss | -1.61% | -2.81% | -7.71% |
| 2024-12-05 |
| Q2 2025 |
| -0.91 |
| -0.91 |
| +0.00% |
| $0 |
| ➖ Inline |
| +8.34% |
| -3.42% |
| -4.14% |
| 2024-09-05 | Q1 2025 | -0.86 | -0.87 | -1.16% | $0 | ❌ Miss | -4.12% | -18.73% | -12.35% |
| 2024-07-11 | Q4 2024 | -0.73 | -1.02 | -39.73% | $0 | ❌ Miss | +4.32% | +13.60% | +3.76% |
| 2024-03-11 | Q3 2024 | -0.77 | -0.84 | -9.09% | $0 | ❌ Miss | — | — | — |
| 2023-12-07 | Q2 2024 | -0.79 | -0.80 | -1.27% | $0 | ❌ Miss | -9.03% | +17.06% | +44.93% |
| 2023-09-07 | Q1 2024 | -0.86 | -0.74 | +1395.35% | $0 | ✅ Beat | -4.52% | -8.03% | -13.28% |
Showing last 8 quarters.